Biogen

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

News

Sage considering cuts after FDA setback

Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the

News

Zuranolone cleared for post-partum depression, but not MDD

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ

News

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma.

News

Biogen wields axe again ahead of Leqembi rollout

Biogen has announced another big round of layoffs and cost-cutting, with 1,000 more workers set to lose their jobs after it shed around 900 last year and shelved various R

News